ERCC3
ERCC3 (General transcription and DNA repair factor IIH helicase/translocase subunit XPB) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Cervical cancer, Skin cancer, Ovarian cancer and 3 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
ATP-dependent 3'-5' DNA helicase/translocase. Binds dsDNA rather than ssDNA, unzipping it in a translocase rather than classical helicase activity. Component of the general transcription and DNA repair factor IIH (TFIIH) core complex. When complexed to CDK-activating kinase (CAK), involved in RNA transcription by RNA polymerase II. The ATPase activity of XPB/ERCC3, but not its helicase activity, is required for DNA opening; it may wrap around the damaged DNA wedging it open, causing localised melting that allows XPD/ERCC2 helicase to anchor. In transcription, TFIIH has an essential role in transcription initiation. Location: Nucleus (UniProt). Locus 2q14.3 (HGNC).
- Cervical cancer: IntOGen driver in 1 cohort (CESC)
- Skin cancer: Open Targets association 0.54 with skin cancer (MONDO_0002898)
- Ovarian cancer: Open Targets association 0.53 with ovarian cancer (MONDO_0008170)
- Colorectal cancer: Open Targets association 0.52 with colorectal cancer (MONDO_0005575)
- Melanoma: Open Targets association 0.55 with melanoma (MONDO_0005105); CIViC evidence names this disease
- Non-small-cell lung cancer: CIViC evidence names this disease
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"ERCC3" OR ABSTRACT:"ERCC3" OR TITLE:"ERCC excision repair 3, TFIIH core complex helicase subunit" OR ABSTRACT:"ERCC excision repair 3, TFIIH core complex helicase subunit" OR TITLE:"General transcription and DNA repair factor IIH helicase/translocase subunit XPB" OR ABSTRACT:"General transcription and DNA repair factor IIH helicase/translocase subunit XPB" OR TITLE:"BTF2" OR ABSTRACT:"BTF2" OR TITLE:"RAD25" OR ABSTRACT:"RAD25" OR TITLE:"Ssl2" OR ABSTRACT:"Ssl2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ERCC3, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ercc3.json. Licence CC BY-NC 4.0.